Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study

Annals of Oncology

Volumn 10, Issue 10, 1999, Pages 1191-1197

  Coiffier, B ^a,k   Neidhardt Berard E M ^a   Tilly, H ^b   Belanger, C ^c   Bouabdallah, R ^d   Haioun, C ^e   Brice, P ^f   Peaud P Y ^g   Pico, J L ^h   Janvier, M ⁱ   Solal Celigny, P ^j   Brousse, N ^c  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CENTRE HOSPITALIER DE VALENCE   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ CENTRE RENÉ HUGUENIN   (France)

^j Clinique Victor Hugo   (France)

^k CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

Fludarabine; Follicular lymphoma; Interferon

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LACTATE DEHYDROGENASE; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON; TENIPOSIDE;

ADULT; AGED; AGING; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; NEUTROPENIA; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INTERFERONS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; SURVIVAL ANALYSIS; TENIPOSIDE; VIDARABINE;

EID: 0344614652     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008347425795     Document Type: Article

References (23)

1. Harris NL, Jaffe ES, Stein H et al. A Revised European-American Classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
2. Pileri SA, Milani M, Fraternali-Orcioni G et al. From the R.E.A.L. Classification to the upcoming WHO scheme: A step toward universal categorization of lymphoma entities? Ann Oncol 1998; 9: 607-12.
3. The Non-Hodgkin's Lymphoma Classification Project. A clinical trial of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-18.
4. The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 1997; 8: 973-8.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
6. Hiddemann W, Unterhalt M, Buske C et al. Treatment of follicular follicle centre lymphomas: Current status and future perspectives. J Intern Med 1997; 740 (Suppl): 55-62.
7. Coiffier B, Salles G, Bastion Y. Prognostic factors in non-Hodgkin's lymphoma. In Magrath IT (ed): The Non-Hodgkin's Lymphomas, 2nd edition. London: Adward Arnold 1997; 739-68.
8. Coiffier B, Bastion Y, Berger F et al. Prognostic factors in follicular lymphomas. Semin Oncol 1993; 20: 89-95.
9. Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autografting for follicular low-grade lymphoma in first remission: The Stanford experience. Blood 1997; 91 (Suppl 1): Abstr 2641.
10. Solal-Celigny P, Lepage E, Brousse N et al. Recombinant interferon-alfa-2b combined with a regimen containing doxorubicin in advanced follicular lymphoma. N Engl J Med 1993; 329: 1608-14.
11. Unterhalt M, Hermann R, Koch P et al. Long-term interferon-alpha maintenance prolongs remission duration in advanced low-grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 1996; 88 (Suppl 1): 453a.
12. Arranz R, Garcia-Alfonso P, Sobrino P et al. Role of interferon-alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16: 1538-46.
13. Smalley RV, Anderson SA, Tuttle RL et al. A randomized comparison of two doses of human lymphoblastoid interferon-alpha in hairy cell leukemia. Blood 1991; 78: 3133-41.
14. Solal-Celigny P, Lepage E, Brousse N et al. Doxorubicin-containing regimen with or without interferon-alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires-86 trial. J Clin Oncol 1998; 16: 2332-8.
15. Smalley R, Weller E, Hawkins M et al. α-interferon in non-Hodgkin's lymphoma: An update of the ECOG I-COPA trial (E6484). Blood 1998; 92 (Suppl 1): 486a.
16. Hagenbeek A, Carde P, Meerwaldt JH et al. Maintenance of remission with human recombinant interferon-alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 41-7.
17. Rohatiner AZS, Gregory W, Peterson B et al. A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma, Proc Am Soc Clin Oncol 1998; 17: 4a.
18. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262-8.
19. Solal-Céligny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma. A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514-9.
20. Hagenbeek A, Eghbali H, Monfardini S et al. Fludarabine versus conventional CVP chemlotherapy in newly diagnosed patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients. American Society of Hematology meeting. Blood; 1998; 92: 315a (Abstr 1294).
21. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75-88.
22. Swan F, Velasquez WS, Tucker S et al. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989; 7: 1518-27.
23. Bastion Y, Berger F, Bryon PA et al. Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 9: 123-9.